Fox News
New drug combo shrinks tumors in most patients facing aggressive cancer type
Saturday, November 21, 2026
Daraxonrasib combined with chemotherapy shrank tumors in 60.7% of pancreatic cancer patients in a trial, with 8.2% experiencing complete tumor disappearance on imaging scans. The drug pairing was tested on patients with an aggressive form of pancreatic cancer. No timeline for regulatory review or availability was provided in the report.
Original reporting:
